Jason S. Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jason S. Kim has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- David John Hunter
Faculty of Medicine and Health, Sydney Musculoskeletal Health, Kolling Institute, The University of Sydney, Sydney, Australia
3 shared publications - Donald D. Anderson
Department of Orthopedics and Rehabilitation, University of Iowa, Iowa City, IA, USA
3 shared publications Carolyn M. Sofka
Department of Radiology and Imaging, Hospital for Special Surgery, New York, NY, USA
2 shared publicationsDaniel J. Betensky
Policy and Innovation eValuation in Orthopaedic Treatments (PIVOT) Center and Orthopaedic and Arthritis Center for Outcomes Research (OrACORe), Department of Orthopaedic Surgery, Brigham and Women’s Hospital, Boston, Massachusetts (D.J.B., C.Y.)
2 shared publications- Daniel M. Cushman
Department of Physical Medicine & Rehabilitation, University of Utah, Salt Lake City, Utah
2 shared publications Dennis Janisse
National Pedorthic Services, Inc., Milwaukee, WI, USA
2 shared publications
Latest Publications
- 1 November 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (11) , 1549-1560
The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity
Glucagon-like peptide-1 receptor agonists (GLP1RAs) lead to substantial weight loss and pain reduction in persons with knee osteoarthritis and obesity. To evaluate the cost-effectiveness of 2 GLP1RAs, semaglutide and tirzepatide, for patients with osteoarthritis and obesity. Osteoarthritis Policy Model, a validated microsimulation model of knee osteoarthritis, to estimate lifetime benefits and costs of weight loss strategies. Published data to derive treatment-related weight loss, pain reduction, and costs of GLP1RAs from the U.S. Office of Health Policy. Persons with knee osteoarthritis and obesity in the United States. The base-case cohort had a Western Ontario and McMaster Universities Osteoarthritis Index pain score of 71 (0 to 100, 100 worst) and a mean body mass index (BMI) of 40 kg/m2. Lifetime. Health care, societal. Semaglutide, tirzepatide, laparoscopic sleeve gastrectomy (LSG), Roux-en-Y gastric bypass (RYGB), and diet and exercise. Quality-adjusted life-years (QALYs), cost, and incremental cost-effectiveness ratios (ICERs). Tirzepatide provided greater health benefits at lower costs than semaglutide and yielded a $57 400 per QALY ICER versus diet and exercise. For those eligible, RYGB provided greater health benefits at lower costs than the 2 GLP1RAs and had a $30 700 per QALY ICER versus LSG. Tirzepatide's ICER was most sensitive to changes in medication costs, treatment efficacy, and cohort baseline BMI. Tirzepatide had a 64% and semaglutide had a 34% probability of being cost-effective at a $100 000 per QALY threshold. Data from multiple sources. Both tirzepatide and semaglutide would be widely considered cost-effective when compared directly with usual care. Tirzepatide would offer the most favorable return on investment to decision makers whose cost-effectiveness thresholds exceed $57 400 per QALY. The Arthritis Foundation and National Institute of Arthritis and Musculoskeletal and Skin Diseases.
- 1 November 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (11) , 1549-1560
The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity
Glucagon-like peptide-1 receptor agonists (GLP1RAs) lead to substantial weight loss and pain reduction in persons with knee osteoarthritis and obesity. To evaluate the cost-effectiveness of 2 GLP1RAs, semaglutide and tirzepatide, for patients with osteoarthritis and obesity. Osteoarthritis Policy Model, a validated microsimulation model of knee osteoarthritis, to estimate lifetime benefits and costs of weight loss strategies. Published data to derive treatment-related weight loss, pain reduction, and costs of GLP1RAs from the U.S. Office of Health Policy. Persons with knee osteoarthritis and obesity in the United States. The base-case cohort had a Western Ontario and McMaster Universities Osteoarthritis Index pain score of 71 (0 to 100, 100 worst) and a mean body mass index (BMI) of 40 kg/m2. Lifetime. Health care, societal. Semaglutide, tirzepatide, laparoscopic sleeve gastrectomy (LSG), Roux-en-Y gastric bypass (RYGB), and diet and exercise. Quality-adjusted life-years (QALYs), cost, and incremental cost-effectiveness ratios (ICERs). Tirzepatide provided greater health benefits at lower costs than semaglutide and yielded a $57 400 per QALY ICER versus diet and exercise. For those eligible, RYGB provided greater health benefits at lower costs than the 2 GLP1RAs and had a $30 700 per QALY ICER versus LSG. Tirzepatide's ICER was most sensitive to changes in medication costs, treatment efficacy, and cohort baseline BMI. Tirzepatide had a 64% and semaglutide had a 34% probability of being cost-effective at a $100 000 per QALY threshold. Data from multiple sources. Both tirzepatide and semaglutide would be widely considered cost-effective when compared directly with usual care. Tirzepatide would offer the most favorable return on investment to decision makers whose cost-effectiveness thresholds exceed $57 400 per QALY. The Arthritis Foundation and National Institute of Arthritis and Musculoskeletal and Skin Diseases.
- Open Access
- 23 December 2024
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 7 (1) , 100563
The PIKASO trial (Preventing Injured Knees from Osteoarthritis: Severity Outcomes): Rationale and design features for a randomized controlled trial
- 23 December 2024
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 7 (1) , 100563
Open AccessThe PIKASO trial (Preventing Injured Knees from Osteoarthritis: Severity Outcomes): Rationale and design features for a randomized controlled trial
- Open Access
- 18 April 2024
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 6 (2) , 100471
Visual narratives in medicine – Bridging the gap in graphic medicine with an illustrated narrative of osteoarthritis
- 18 April 2024
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 6 (2) , 100471
Open AccessVisual narratives in medicine – Bridging the gap in graphic medicine with an illustrated narrative of osteoarthritis
- Open Access
- 15 November 2023
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (2) , 209-212
Stepping Up Counseling and Referral to Effective Physical Activity Interventions for Adults With Osteoarthritis
- 15 November 2023
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (2) , 209-212
Open AccessStepping Up Counseling and Referral to Effective Physical Activity Interventions for Adults With Osteoarthritis
- Open Access
- 16 September 2023
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 5 (4) , 100408
The OARSI Joint Effort Initiative: Priorities for osteoarthritis management program implementation and research 2024–2028
- 16 September 2023
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 5 (4) , 100408
Open AccessThe OARSI Joint Effort Initiative: Priorities for osteoarthritis management program implementation and research 2024–2028
- 9 November 2022
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 31 (2) , 249-257
Reproducibility of T1ρ and T2 quantification in a multi-vendor multi-site study
- 9 November 2022
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 31 (2) , 249-257
Reproducibility of T1ρ and T2 quantification in a multi-vendor multi-site study
- Open Access
- 15 October 2022
- Published by SAGE Publications in Foot & Ankle Orthopaedics
- Vol. 7 (4)
Summary Report of the Arthritis Foundation and the American Orthopaedic Foot & Ankle Society’s Symposium on Targets for Osteoarthritis Research: Part 1: Epidemiology, Pathophysiology, and Current Imaging Approaches
This first of a 2-part series of articles recounts the key points presented in a collaborative symposium sponsored jointly by the Arthritis Foundation and the American Orthopaedic Foot & Ankle Society with the intent to survey the state of scientific knowledge related to incidence, diagnosis, pathologic mechanisms, and injection treatment options for osteoarthritis (OA) of the foot and ankle. A meeting was held virtually on December 3, 2021. A group of experts were invited to present brief synopses of the current state of knowledge and research in this area. Part 1 overviews areas of epidemiology and pathophysiology, current approaches in imaging, diagnostic and therapeutic injections, and genetics. Opportunities for future research are discussed. The OA scientific community, including funding agencies, academia, industry, and regulatory agencies, must recognize the needs of patients that suffer from arthritis of foot and ankle. The foot and ankle contain a myriad of interrelated joints and tissues that together provide a critical functionality. When this functionality is compromised by OA, significant disability results, yet the foot and ankle are generally understudied by the research community. Level of Evidence: Level V - Review Article/Expert Opinion.
- 15 October 2022
- Published by SAGE Publications in Foot & Ankle Orthopaedics
- Vol. 7 (4)
Open AccessSummary Report of the Arthritis Foundation and the American Orthopaedic Foot & Ankle Society’s Symposium on Targets for Osteoarthritis Research: Part 1: Epidemiology, Pathophysiology, and Current Imaging Approaches
This first of a 2-part series of articles recounts the key points presented in a collaborative symposium sponsored jointly by the Arthritis Foundation and the American Orthopaedic Foot & Ankle Society with the intent to survey the state of scientific knowledge related to incidence, diagnosis, pathologic mechanisms, and injection treatment options for osteoarthritis (OA) of the foot and ankle. A meeting was held virtually on December 3, 2021. A group of experts were invited to present brief synopses of the current state of knowledge and research in this area. Part 1 overviews areas of epidemiology and pathophysiology, current approaches in imaging, diagnostic and therapeutic injections, and genetics. Opportunities for future research are discussed. The OA scientific community, including funding agencies, academia, industry, and regulatory agencies, must recognize the needs of patients that suffer from arthritis of foot and ankle. The foot and ankle contain a myriad of interrelated joints and tissues that together provide a critical functionality. When this functionality is compromised by OA, significant disability results, yet the foot and ankle are generally understudied by the research community. Level of Evidence: Level V - Review Article/Expert Opinion.
- Open Access
- 14 October 2022
- Published by SAGE Publications in Foot & Ankle Orthopaedics
- Vol. 7 (4)
Summary Report of the Arthritis Foundation and the American Orthopaedic Foot & Ankle Society’s Symposium on Targets for Osteoarthritis Research: Part 2: Treatment Options
This second of a 2-part series of articles recounts the key points presented in a collaborative symposium sponsored jointly by the Arthritis Foundation and the American Orthopaedic Foot & Ankle Society with the intent to survey current treatment options for osteoarthritis (OA) of the foot and ankle. A meeting was held virtually on December 10, 2021. A group of experts were invited to present brief synopses of the current state of knowledge and research in this area. Topics were chosen by meeting organizers, who then identified and invited the expert speakers. Part 2 overviews the current treatment options, including orthotics, non–joint destructive procedures, as well as arthroscopies and arthroplasties in ankles and feet. Opportunities for future research are also discussed, such as developments in surgical options for ankle and the first metatarsophalangeal joint. The OA scientific community, including funding agencies, academia, industry, and regulatory agencies, must recognize the importance to patients of addressing the foot and ankle with improved basic, translational, and clinical research. Level of Evidence: Level V, review article/expert opinion.
- 14 October 2022
- Published by SAGE Publications in Foot & Ankle Orthopaedics
- Vol. 7 (4)
Open AccessSummary Report of the Arthritis Foundation and the American Orthopaedic Foot & Ankle Society’s Symposium on Targets for Osteoarthritis Research: Part 2: Treatment Options
This second of a 2-part series of articles recounts the key points presented in a collaborative symposium sponsored jointly by the Arthritis Foundation and the American Orthopaedic Foot & Ankle Society with the intent to survey current treatment options for osteoarthritis (OA) of the foot and ankle. A meeting was held virtually on December 10, 2021. A group of experts were invited to present brief synopses of the current state of knowledge and research in this area. Topics were chosen by meeting organizers, who then identified and invited the expert speakers. Part 2 overviews the current treatment options, including orthotics, non–joint destructive procedures, as well as arthroscopies and arthroplasties in ankles and feet. Opportunities for future research are also discussed, such as developments in surgical options for ankle and the first metatarsophalangeal joint. The OA scientific community, including funding agencies, academia, industry, and regulatory agencies, must recognize the importance to patients of addressing the foot and ankle with improved basic, translational, and clinical research. Level of Evidence: Level V, review article/expert opinion.
- 14 July 2022
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 56, 152070
FDA/Arthritis Foundation osteoarthritis drug development workshop recap: Assessment of long-term benefit
- 14 July 2022
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 56, 152070
FDA/Arthritis Foundation osteoarthritis drug development workshop recap: Assessment of long-term benefit
- Open Access
- 23 April 2022
- Published by Springer Nature in Cureus
- Vol. 14 (4) , e24422
Anaplastic Lymphoma Kinase Positive Mesenteric Inflammatory Myofibroblastic Tumor in Adult Woman
Inflammatory myofibroblastic tumors (IMTs) are rare mesenchymal neoplasms containing spindle cells and inflammatory components that can be locally aggressive. They have unclear biological behavior and may recur after resection. A 31-year-old woman presented with three months of cough, fatigue, weight loss, abdominal pain, anemia, and elevated inflammatory markers. CT showed a large well-circumscribed enhancing mass in the right colic mesentery. The patient underwent a laparoscopic right colectomy. Pathologic review showed fascicular spindle cells with admixed chronic inflammatory cells. Cells stained diffusely positive for SMA and anaplastic lymphoma kinase (ALK), diagnostic of an IMT. Post-operatively, the patient reported symptom resolution and had normalization of lab values. She remains disease-free at 20 months. IMT is rare in adults, accounting for 0.7%-1.0% of lung tumors. Up to 30% of patients present with elevated inflammatory markers. On imaging, IMTs are soft tissue masses with variable enhancement and fibrosis, often suspected to be malignant neoplasms. Up to 80% of IMTs are driven by altered tyrosine kinase signaling and half of IMTs express ALK, which may be treated in unresectable/recurrent cases using ALK-inhibitors. IMT may recur in 10%-15% of patients. The roles of adjuvant treatments are unclear given the rarity and unpredictable biological behavior. Long-term follow-up with regular radiologic and laboratory surveillance is recommended given possible local recurrence. IMTs are best managed in a multidisciplinary setting given their unpredictable nature. Surgery is the mainstay of IMT treatment with long-term control expected in >80% of adult patients.
- 23 April 2022
- Published by Springer Nature in Cureus
- Vol. 14 (4) , e24422
Open AccessAnaplastic Lymphoma Kinase Positive Mesenteric Inflammatory Myofibroblastic Tumor in Adult Woman
Inflammatory myofibroblastic tumors (IMTs) are rare mesenchymal neoplasms containing spindle cells and inflammatory components that can be locally aggressive. They have unclear biological behavior and may recur after resection. A 31-year-old woman presented with three months of cough, fatigue, weight loss, abdominal pain, anemia, and elevated inflammatory markers. CT showed a large well-circumscribed enhancing mass in the right colic mesentery. The patient underwent a laparoscopic right colectomy. Pathologic review showed fascicular spindle cells with admixed chronic inflammatory cells. Cells stained diffusely positive for SMA and anaplastic lymphoma kinase (ALK), diagnostic of an IMT. Post-operatively, the patient reported symptom resolution and had normalization of lab values. She remains disease-free at 20 months. IMT is rare in adults, accounting for 0.7%-1.0% of lung tumors. Up to 30% of patients present with elevated inflammatory markers. On imaging, IMTs are soft tissue masses with variable enhancement and fibrosis, often suspected to be malignant neoplasms. Up to 80% of IMTs are driven by altered tyrosine kinase signaling and half of IMTs express ALK, which may be treated in unresectable/recurrent cases using ALK-inhibitors. IMT may recur in 10%-15% of patients. The roles of adjuvant treatments are unclear given the rarity and unpredictable biological behavior. Long-term follow-up with regular radiologic and laboratory surveillance is recommended given possible local recurrence. IMTs are best managed in a multidisciplinary setting given their unpredictable nature. Surgery is the mainstay of IMT treatment with long-term control expected in >80% of adult patients.